Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance

Treatment-induced neuroendocrine transdifferentiation (NEtD) complicates therapies for metastatic prostate cancer (PCa). Based on evidence that PCa cells can transdifferentiate to other neuroectodermally-derived cell lineages in vitro, we proposed that NEtD requires first an intermediary reprogrammi...

Descripción completa

Detalles Bibliográficos
Autores principales: Nouri, Mannan, Caradec, Josselin, Lubik, Amy Anne, Li, Na, Hollier, Brett G., Takhar, Mandeep, Altimirano-Dimas, Manuel, Chen, Mengqian, Roshan-Moniri, Mani, Butler, Miriam, Lehman, Melanie, Bishop, Jennifer, Truong, Sarah, Huang, Shih-Chieh, Cochrane, Dawn, Cox, Michael, Collins, Colin, Gleave, Martin, Erho, Nicholas, Alshalafa, Mohamed, Davicioni, Elai, Nelson, Colleen, Gregory-Evans, Sheryl, Karnes, R. Jeffrey, Jenkins, Robert B., Klein, Eric A., Buttyan, Ralph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386661/
https://www.ncbi.nlm.nih.gov/pubmed/28145883
http://dx.doi.org/10.18632/oncotarget.14850

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386661/
https://www.ncbi.nlm.nih.gov/pubmed/28145883
http://dx.doi.org/10.18632/oncotarget.14850

Ejemplares similares